IGF-1 DES (Des(1-3) IGF-1)
Truncated IGF-1 Analog | Localized Muscle Growth
Community Research
Join others researching IGF-1 DES — share findings, ask questions, and learn from real experiences
IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is approximately 10x greater potency than native IGF-1, but with an extremely short half-life of 20-30 minutes. This short duration of action is considered a feature rather than a limitation -- it allows for site-specific injection into target muscles immediately post-workout, promoting localized growth with reduced systemic exposure.
IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, driving both muscle hypertrophy and hyperplasia. Because it lacks the tripeptide Gly-Pro-Glu at the N-terminus, it cannot bind to IGFBPs that normally sequester ~98% of circulating IGF-1. This means the entire administered dose remains bioavailable. The very short half-life confines its activity to the local injection site, where it stimulates satellite cell proliferation and differentiation, protein synthesis, and nutrient uptake in the targeted muscle tissue.
Molecular Data
Research Indications
Site-specific muscle growth via direct intramuscular injection into target muscle post-workout.
Stimulates satellite cell proliferation and differentiation, potentially creating new muscle fibers.
Accelerates local tissue recovery in the injected muscle group after training.
Promotes repair and regeneration at the injection site through IGF-1R activation.
Dosing Protocols
Intramuscular injection directly into the target muscle immediately post-workout. The extremely short half-life means timing and site selection are critical. Consume fast carbohydrates after injection to mitigate hypoglycemia risk.
Beginner Protocol
20-30mcg
Post-workout, injected into trained muscle
IM (site-specific)
Intermediate
30-50mcg
Advanced
50mcg
Post-workout, split across multiple trained muscles
Reconstitution Instructions
IGF-1 DES lyophilized powder
Bacteriostatic water or 0.6% acetic acid
Insulin syringes (29-31 gauge)
Alcohol swabs
1 Allow vial to reach room temperature (15-30 min)
2 Sanitize rubber stopper with alcohol swab
3 Calculate desired concentration (e.g., 1mg in 1mL = 1000mcg/mL)
4 Inject diluent slowly along the vial wall
5 Gently swirl -- do not shake
6 Allow 2-5 minutes for complete dissolution
7 Store reconstituted solution at 2-8C
8 Use within 7 days when reconstituted with BAC water
9 Acetic acid reconstitution extends stability
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
Hypoglycemia -- consume carbohydrates after injection
Localized swelling and soreness at injection site
Increased pump in targeted muscles
Mild lightheadedness shortly after injection
Stop Signs - Discontinue if:
Severe or recurring hypoglycemia despite carbohydrate intake
Disproportionate or asymmetric muscle growth
Unusual growths, lumps, or rapid mole changes
Persistent pain, redness, or infection at injection site
Signs of systemic IGF-1 excess (jaw growth, organ enlargement)
Contraindications
Not approved for human use -- research chemical only
Cancer history or active malignancy (IGF-1 promotes cell proliferation)
Diabetes or impaired glucose regulation
WADA prohibited substance -- causes failed drug tests
Quality Checklist
Good Signs
HPLC purity >95%
Mass spectrometry confirmation of truncated sequence
Cold storage maintained (-20C lyophilized)
Certificate of analysis from reputable source
Warning Signs
Research chemical only -- never approved for human use
No human clinical trials exist
Extremely short half-life requires precise timing
Bad Signs
Hypoglycemia risk -- blood sugar can drop rapidly after injection
Potential for disproportionate muscle growth with repeated site-specific use
Black market quality varies -- degraded product is common
Cancer proliferation concern -- elevated IGF-1 activity promotes cell growth
Frequently Asked Questions
Why is IGF-1 DES injected directly into muscles?
IGF-1 DES has a 20-30 minute half-life and doesn't bind IGF binding proteins, making it 10x more potent but short-acting. Direct intramuscular injection confines its activity to the targeted muscle immediately post-workout, enabling localized hypertrophy without systemic IGF-1 excess.
Will IGF-1 DES cause hypoglycemia?
Yes. IGF-1 DES lowers blood glucose by promoting glucose uptake into muscle tissue. You must consume 20-40g of fast carbohydrates immediately after injection. Monitor blood glucose early in use and never inject before sleep due to overnight hypoglycemia risk.
Can I use IGF-1 DES if I'm on a keto diet?
Not safely. The mandatory carbohydrate intake after IGF-1 DES injection will break ketosis. If keto is your goal, use alternatives like GH or ipamorelin instead. The post-injection carbs are non-negotiable for safety.
Does IGF-1 DES cause cancer risk?
IGF-1 promotes cell proliferation, and elevated systemic IGF-1 is linked to multiple cancers in the UK Biobank study. DES minimizes systemic exposure through its short half-life and local injection, but cancer risk remains a theoretical concern with any IGF-1 product.
References
First identification and characterization of Des(1-3) IGF-1 as a naturally occurring truncated form of IGF-1 in human brain tissue, establishing that the N-terminal tripeptide deletion occurs endogenously.
Des(1-3) IGF-1 demonstrated approximately 10-fold greater potency than intact IGF-1 in stimulating protein synthesis and cell proliferation, directly attributable to its inability to bind IGF binding proteins.
Des(1-3) IGF-1 and LR3-IGF-1 were significantly more potent than native IGF-1 in reversing dexamethasone-induced muscle wasting in rats, with truncated and modified variants showing superior anabolic activity.
Higher circulating IGF-1 associated with increased risks of colorectal, breast, prostate, and thyroid cancers in >395,000 UK Biobank participants, underscoring the cancer risk of sustained IGF-1 pathway activation.
Related Peptides
Testosterone increases IGF-1 receptor density and satellite cell number, amplifying the local effects of IGF-1 DES at the injection site.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.